HC Wainwright reaffirmed their buy rating on shares of Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) in a research report released on Thursday morning, Benzinga reports. They currently have a $60.00 price target on the stock.
Several other brokerages also recently commented on LBPH. Cantor Fitzgerald boosted their price objective on shares of Longboard Pharmaceuticals from $60.00 to $90.00 and gave the company an overweight rating in a research report on Monday, July 1st. Evercore ISI boosted their price objective on shares of Longboard Pharmaceuticals from $57.00 to $80.00 and gave the company an outperform rating in a research report on Tuesday, July 2nd. Wedbush boosted their target price on shares of Longboard Pharmaceuticals from $32.00 to $34.00 and gave the stock an outperform rating in a research note on Friday, May 3rd. Citigroup upped their price target on shares of Longboard Pharmaceuticals from $40.00 to $45.00 and gave the stock a buy rating in a report on Tuesday, July 2nd. Finally, B. Riley upped their price target on shares of Longboard Pharmaceuticals from $30.00 to $36.00 and gave the stock a buy rating in a report on Tuesday, June 11th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of Buy and a consensus price target of $56.00.
Read Our Latest Report on Longboard Pharmaceuticals
Longboard Pharmaceuticals Trading Down 0.2 %
Longboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.06. On average, sell-side analysts expect that Longboard Pharmaceuticals will post -1.82 earnings per share for the current fiscal year.
Institutional Trading of Longboard Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of LBPH. Jennison Associates LLC acquired a new stake in Longboard Pharmaceuticals in the fourth quarter valued at $2,899,000. CIBC Asset Management Inc increased its holdings in Longboard Pharmaceuticals by 46.8% in the fourth quarter. CIBC Asset Management Inc now owns 212,178 shares of the company’s stock valued at $1,279,000 after purchasing an additional 67,607 shares during the period. Platinum Investment Management Ltd. acquired a new stake in Longboard Pharmaceuticals in the fourth quarter valued at $766,000. Parkman Healthcare Partners LLC increased its holdings in Longboard Pharmaceuticals by 20.8% in the fourth quarter. Parkman Healthcare Partners LLC now owns 429,892 shares of the company’s stock valued at $2,592,000 after purchasing an additional 73,935 shares during the period. Finally, Denali Advisors LLC acquired a new stake in Longboard Pharmaceuticals in the first quarter valued at $201,000. 63.28% of the stock is currently owned by institutional investors and hedge funds.
Longboard Pharmaceuticals Company Profile
Longboard Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.
Recommended Stories
- Five stocks we like better than Longboard Pharmaceuticals
- Trading Halts Explained
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- What is a Special Dividend?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Most Effectively Use the MarketBeat Earnings Screener
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Longboard Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longboard Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.